|
Arena’s Belviq Avoids a REMS, But Saddled With Six Postmarket Studies
The FDA has approved its first weight-loss drug in 13 years, giving the OK to Arena Pharmaceutical’s Belviq, while requiring a hefty dose of postmarket studies on cardiovascular events.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives